Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study

By sjmartinez • December 26, 2025

Pistilli B, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Jañez NM, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Tsurutani J, Kalinsky K, Liedke PER, Carroll D, Khan S, Rugo HS, Xu B, Bardia A; TROPION-Breast01 investigators. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study. Ann Oncol. 2025 Dec 23:S0923-7534(25)06337-9. doi: 10.1016/j.annonc.2025.12.017. Epub ahead of print. PMID: 41448362.

Tags: Dato-DXd, Datopotamab deruxtecan, Hematology/Oncology, HER2-negative breast cancer, HR+ breast cancer, overall survival, Publications, TROPION-Breast01

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study

Rugo HS, Jhaveri K, Pernas S, Pistilli B, Im SA, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu[...]

The Role of Immunotherapy in Breast Cancer and Mechanisms of Immune Escape: What Surgeons Need to Know

Graham DM, Lofftus S, Azizi L, Berkowitz MJ, Teshome M. The Role of Immunotherapy in Breast Cancer and Mechanisms of Immune Escape: What Surgeons Need[...]

Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial

Wainberg ZA, Lee KW, Kim JG, Devoe C, Strickler JH, Baum J, Jia C, Kagey MH, Sirard CA, Stein A, Scott AJ, Pelster M, Moehler[...]